• Therapie der Zukunft: we fight your cancer

177Lu-PSMA is safe and effective for octogenarians

177Lu-PSMA is safe and effective for octogenarians

A study evaluating the efficacy and safety of 177Lu-PSMA radioligand therapy for treating mCRPC in octogenarians demonstrated that radioligand therapy is safe and effective also in elderly patients. Moreover, patients who have not previously undergone chemotherapy had a better and longer-lasting response both in terms of overall and progression-free survival.



PSA response rate



Overall survival

6.5 months

10.5 months

Progression-free survival

11.8 months

20.7 months

Treatment-emergent grade 3 toxicities were low, supporting the conclusion that 177Lu-PSMA RLT is a safe and effective option for elderly mCRPC patients.